Furthermore, it has been shown that a PPARα agonist stimulated corneal nerve regeneration in patients with T2DM (Teo et al., 2023) and protected the corneal nerve from degeneration in a mouse model of diabetes (Matlock et al., 2020), suggesting that the use of the PPARα agonist may be promising strategy for treating DPN. Here, PPARA is linked to diabetes mellitus.